The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Locally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy—Results from ACRIN 6657/I-SPY TRIAL
Open accessAbstract
PURPOSE: To compare magnetic resonance (MR) imaging findings and clinical assessment for prediction of pathologic response to neoadjuvant chemotherapy (NACT) in patients with stage II or III breast cancer. MATERIALS AND METHODS: The HIPAA-compliant protocol and the informed consent process were approved by the American College of Radiology Institutional Review Board and local-site institutional review boards. Women with invasive breast cancer of 3 cm or greater undergoing NACT with an anthracycline-based regimen, with or without a taxane, were enrolled between May 2002 and March 2006. MR imaging was performed before NACT (first examination), after one cycle of anthracyline-based treatment (second examination), between the anthracycline-based regimen and taxane (third examination), and after all chemotherapy and prior to surgery (fourth examination). MR imaging assessment included measurements of tumor longest diameter and volume and peak signal enhancement ratio. Clinical size was also recorded at each time point. Change in clinical and MR imaging predictor variables were compared for the ability to predict pathologic complete response (pCR) and residual cancer burden (RCB). Univariate and multivariate random-effects logistic regression models were used to characterize the ability of tumor response measurements to predict pathologic outcome, with area under the receiver operating characteristic curve (AUC) used as a summary statistic. RESULTS: Data in 216 women (age range, 26-68 years) with two or more imaging time points were analyzed. For prediction of both pCR and RCB, MR imaging size measurements were superior to clinical examination at all time points, with tumor volume change showing the greatest relative benefit at the second MR imaging examination. AUC differences between MR imaging volume and clinical size predictors at the early, mid-, and posttreatment time points, respectively, were 0.14, 0.09, and 0.02 for prediction of pCR and 0.09, 0.07, and 0.05 for prediction of RCB. In multivariate analysis, the AUC for predicting pCR at the second imaging examination increased from 0.70 for volume alone to 0.73 when all four predictor variables were used. Additional predictive value was gained with adjustments for age and race. CONCLUSION: MR imaging findings are a stronger predictor of pathologic response to NACT than clinical assessment, with the greatest advantage observed with the use of volumetric measurement of tumor response early in treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
Harrell, F. E. (2001) · Springer Series in Statistics · doi:10.1007/978-1-4757-3462-1 · Cited by 9,195
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
Fisher, B., Bryant, J., Wolmark, N., Mamounas, E., Brown, A., Fisher, E. R., Wickerham, D. L., Begovic, M., DeCillis, A., Robidoux, A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2672 · Cited by 2,165
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
Symmans, W. F., Peintinger, F., Hatzis, C., Rajan, R., Kuerer, H., Valero, V., Assad, L., Poniecka, A., Hennessy, B., Green, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.6823 · Cited by 1,654
Berg, W. A., Gutierrez, L., NessAiver, M. S., Carter, W. B., Bhargavan, M., Lewis, R. S., & Ioffe, O. B. (2004) · Radiology · doi:10.1148/radiol.2333031484 · Cited by 1,439
Wolmark, N., Wang, J., Mamounas, E., Bryant, J., & Fisher, B. (2001) · JNCI Monographs · doi:10.1093/oxfordjournals.jncimonographs.a003469 · Cited by 1,299
I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
Barker, A., Sigman, C., Kelloff, G., Hylton, N., Berry, D., & Esserman, L. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.68 · Cited by 766
Self-citationTemporal sampling requirements for the tracer kinetics modeling of breast disease
Henderson, E., Rutt, B. K., & Lee, T.-Y. (1998) · Magnetic Resonance Imaging · doi:10.1016/s0730-725x(98)00130-1 · Cited by 263
MRI detection of distinct incidental cancer in women with primary breast cancer studied in IBMC 6883
Schnall, M. D., Blume, J., Bluemke, D. A., DeAngelis, G. A., DeBruhl, N., Harms, S., Heywang-Köbrunner, S. H., Hylton, N., Kuhl, C. K., Pisano, E. D., et al. (2005) · Journal of Surgical Oncology · doi:10.1002/jso.20381 · Cited by 165
Self-citationWeatherall, P. T., Evans, G. F., Metzger, G. J., Saborrian, M. H., & Leitch, A. M. (2001) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.1124 · Cited by 162
Self-citation
Cited by
Predicting cancer outcomes with radiomics and artificial intelligence in radiology
Bera, K., Braman, N., Gupta, A., Velcheti, V., & Madabhushi, A. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00560-7 · Cited by 819
Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival
Magbanua, M. J. M., Swigart, L. B., Wu, H.-T., Hirst, G. L., Yau, C., Wolf, D. M., Tin, A., Salari, R., Shchegrova, S., Pawar, H., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.007 · Cited by 462
Self-citationEsserman, L. J., Berry, D. A., DeMichele, A., Carey, L., Davis, S. E., Buxton, M., Hudis, C., Gray, J. W., Perou, C., Yau, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.2779 · Cited by 438
Self-citationShukla‐Dave, A., Obuchowski, N. A., Chenevert, T. L., Jambawalikar, S., Schwartz, L. H., Malyarenko, D., Huang, W., Noworolski, S. M., Young, R. J., Shiroishi, M. S., et al. (2019) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.26518 · Cited by 389
Self-citationModels and methods for analyzing DCE‐MRI: A review
Khalifa, F., Soliman, A., El‐Baz, A., Abou El‐Ghar, M., El‐Diasty, T., Gimel'farb, G., Ouseph, R., & Dwyer, A. C. (2014) · Medical Physics · doi:10.1118/1.4898202 · Cited by 322
Metadata
- Authors
- Hylton, N. M., Blume, J. D., Bernreuter, W. K., Pisano, E. D., Rosen, M. A., Morris, E. A., Weatherall, P. T., Lehman, C. D., Newstead, G. M., Polin, S., Marques, H. S., Esserman, L. J., & Schnall, M. D.
- Venue
- Radiology
- Published
- 2012-06
- Volume
- 263
- Issue
- 3
- Pages
- 663-672
- ISSN
- 0033-8419 (ISSN-L)
- 1527-1315
- OpenAlex
- W2038833688
- Cited by
- 502
- References
- 11
- FWCI
- 23.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Locally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy—Results from ACRIN 6657/I-SPY TRIAL. https://app.cochat.ai/papers/10.1148/radiol.12110748
- The paper
- Hylton, N. M., Blume, J. D., Bernreuter, W. K., Pisano, E. D., Rosen, M. A., Morris, E. A., Weatherall, P. T., Lehman, C. D., Newstead, G. M., Polin, S., Marques, H. S., Esserman, L. J., & Schnall, M. D. (2012). Locally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy—Results from ACRIN 6657/I-SPY TRIAL. Radiology. https://doi.org/10.1148/radiol.12110748
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.